Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 6/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL581501 | 0.90 | EGFR (0.48) | EGFRGAAKDM4EHSD17B10HIF1A | |
| SCHEMBL3951791 | 0.89 | CFD (0.45) | EGFRGAAKDM4EHSD17B10PPARA | |
| SCHEMBL580201 | 0.88 | EPHX2 (0.40) | EGFRGAAKDM4EPPARASMN1; SMN2 | |
| SCHEMBL4299252 | 0.87 | KDM4C (0.37) | EGFRGAAKDM4EHSD17B10PPARA | |
| SCHEMBL3950219 | 0.87 | ALDH1A1 (0.38) | EGFRGAAKDM4EHSD17B10PPARA | |
| SCHEMBL581259 | 0.84 | KDM4C (0.42) | EGFRGAAKDM4EPPARAPPARG | |
| SCHEMBL581497 | 0.84 | PPARA (0.40) | EGFRGAAKDM4EPPARAPPARG | |
| SCHEMBL580229 | 0.83 | PPARA (0.55) | EGFRSYKKDM4EPPARAALDH1A1 | |
| SCHEMBL27545640 | 0.83 | GAA (0.42) | EGFRGAAKDM4EPPARAPPARG | |
| SCHEMBL4299257 | 0.83 | SERPINE1 (0.36) | EGFRGAAKDM4EPPARASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027076-A1 | COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY | GNT PHARMA CO LTD (KR) | 2026-01-29 | — | — | US | claimed |
| US-12433861-B2 | Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy | GNT PHARMA CO., LTD. (KR) | 2025-10-07 | — | — | US | claimed |
| US-20230390231-A1 | COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY | GNT PHARMA CO., LTD. (KR) | 2023-12-07 | — | — | US | claimed |
| US-11826329-B2 | Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy | GNT PHARMA CO., LTD. (KR) | 2023-11-28 | — | — | US | claimed |
| EP-4117648-A1 | COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY | GNT Pharma Co., Ltd (KR) | 2023-01-18 | — | — | EP | claimed |
| CN-115515573-A | Compositions and methods for treating reperfusion injury or bleeding following recanalization | GNT制药有限公司 | 2022-12-23 | — | — | CN | claimed |
| WO-2021181159-A1 | COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY | GNT PHARMA CO., LTD. (KR) | 2021-09-16 | — | — | WO | claimed |
| US-20210283080-A1 | COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY | GNT PHARMA CO., LTD. (KR) | 2021-09-16 | — | — | US | claimed |
| EP-2417972-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING BURN INJURIES | NEUROTECH PHARMACEUTICALS CO LTD (KR) | 2017-06-14 | — | — | EP | claimed |
| EP-1551793-B1 | TETRAFLUOROBENZYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ACUTE AND CHRONIC NEURODEGENERATIVE DISEASES IN CENTRAL NERVOUS SYSTEM CONTAINING THE SAME | AMKOR PHARMA INC (US) | 2016-01-20 | — | — | EP | claimed |
| US-20120289602-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING BURN INJURIES | ARAONTECH CO., LTD. (KR) | 2012-11-15 | — | — | US | claimed |
| EP-2417972-A2 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING BURN INJURIES | Neurotech Pharmaceuticals Co., Ltd. (KR) | 2012-02-15 | — | — | EP | claimed |
| US-20070298129-A1 | Compounds and compositions for treating neuronal death or neurological dysfunction | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2007-12-27 | — | — | US | claimed |
| EP-1551793-A4 | TETRAFLUOROBENZYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ACUTE AND CHRONIC NEURODEGENERATIVE DISEASES IN CENTRAL NERVOUS SYSTEM CONTAINING THE SAME | NEUROTECH CO LTD (KR) | 2007-04-04 | — | — | EP | claimed |
| US-20070049565-A1 | Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2007-03-01 | — | — | US | claimed |
| WO-2006126825-A1 | COMPOSITION COMPRISING TETRAFLUOROBENZYL DERIVATIVES OR SALTS OF THEREOF FOR INJECTION | CHOONGWAE PHARMA CORPORATION (KR) | 2006-11-30 | — | — | WO | claimed |
| US-6927303-B2 | Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same | NEUROTECH CO., LTD. (KR) | 2005-08-09 | — | — | US | claimed |
| EP-1551793-A1 | TETRAFLUOROBENZYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ACUTE AND CHRONIC NEURODEGENERATIVE DISEASES IN CENTRAL NERVOUS SYSTEM CONTAINING THE SAME | Neurotech Co., Ltd. (KR) | 2005-07-13 | — | — | EP | claimed |
| US-20040209957-A1 | Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2004-10-21 | — | — | US | claimed |
| WO-2004000786-A1 | TETRAFLUOROBENZYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ACUTE AND CHRONIC NEURODEGENERATIVE DISEASES IN CENTRAL NERVOUS SYSTEM CONTAINING THE SAME | NEUROTECH CO., LTD. (KR) | 2003-12-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12433861-B2 | Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy | PLAT, SERPINE1, SERPINC1 | EGFR 100/4885SYK 472/4885GAA 170/4885 |
| US-11826329-B2 | Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy | PLAT, SERPINE1, SERPINC1 | EGFR 100/4885SYK 472/4885GAA 170/4885 |
| US-20230390231-A1 | COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY | PLAT, SERPINE1, SERPINC1 | EGFR 100/4885SYK 472/4885GAA 170/4885 |
| US-20210283080-A1 | COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY | PLAT, SERPINE1, SERPINC1 | EGFR 100/4885SYK 472/4885GAA 170/4885 |
| US-20070298129-A1 | Compounds and compositions for treating neuronal death or neurological dysfunction | BCL2, BAX, SMN1; SMN2 | EGFR 2671/4885SYK 4769/4885GAA 43/4885 |
| US-20120289602-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING BURN INJURIES | CTSA, CFTR, CPT1A | EGFR 4234/4885SYK 892/4885GAA 301/4885 |
| US-20260027076-A1 | COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY | FGB, PLAT, CTSH | EGFR 169/4885SYK 1090/4885GAA 474/4885 |
| US-20070049565-A1 | Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction | BAD, MAP1LC3B, XIAP | EGFR 2579/4885SYK 4715/4885GAA 45/4885 |
| US-20040209957-A1 | Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same | HTT, BDNF, APP | EGFR 510/4885SYK 1823/4885GAA 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.